A 10-Year Real-World Analysis of Omalizumab Use in Chronic Spontaneous Urticaria Patients at a Dermatology Clinic

The majority of patients with CSU in this study responded well to omalizumab, with a significant proportion achieving complete responses. Additionally, higher IgE levels (>20 IU/ml) were associated with a greater likelihood of full response to treatment. These findings suggest that omalizumab is an effective agent for CSU, with the possibility of enhanced response in patients with elevated IgE levels.